Fig. 1

TP63 is associated human LUSC carcinogenesis and early lung cancer progression. a TP63 amplification frequency in TCGA samples by cancer types. The top 10 cancer types ranked by TP63 amplification frequencies are shown. b Transcription factors ranked by amplification frequencies in the TCGA LUSC samples. The vertical axis showed the amplification frequency for each TF in TCGA LUSC, and the horizontal axis shows the ranking of TFs by the amplification frequency. c TP63 expression z-scores in TCGA primary tumor samples relative to normal samples by cancer types. The top 10 cancer types ranked by TP63 overexpression are shown. d Transcription factors ranked by logFC comparing TCGA LUSC tumor to normal samples. The vertical axis shows the logFC of each TF and the horizontal axis shows the ranking of TFs by the logFC. e–f Boxplots show the TP63 isoform (TAp63 and dNp63) expression levels between normal and primary tumor samples in (e) TCGA LUSC and (f) across bronchial PML histological grades in Beane et al. (Mild/Mod/Sev Dysp = Mild/Moderate/Severe Dysplasia; CIS = carcinoma in situ). *p < 0.05, **p < 0.01, ***p < 0.001. g Top 10 TFs responsible for genes upregulated in LUSC versus normal samples based on BART cancer. h Boxplots show the TEADs expression levels across bronchial PML histological grades in Beane et al. Only significant increase with higher histological grades are marked. ***p < 0.001